U.S. Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
38.75-0.30 (-0.77%)
At close: 4:02PM EDT

38.73 -0.02 (-0.05%)
After hours: 5:18PM EDT

People also watch
AZNNVSSNYLLYBMY
  • A
    Anonymous
    Anonymous
    GSK stock is undervalued now. R&D change is positive. I am seeking for stable EPS and revenue in this overvalued market.
  • J
    Joe
    Joe
    Don't buy GSK if you are looking for a stock split or buyout, I guarantee you will be chased out of this stock when traders want to drop it back in the 30's, happens all the time. Buy it if you are looking for a long term nice steady income buy GSK, and Always buy more when it drops below 40. I have been holding GSK since 2003 and couldn't be happier.
  • m
    mark
    mark
    $AGEN conversation
    I heard today the FDA Ad Comm to review and make recommendations on safety, effectiveness of $GSK Shirgrix vaccine with $Agen adjuvant on Sep 13.

    Any opinions on this?
  • r
    romypostit
    romypostit
    does GSK make polio vaccine,i know Great Britain is donating hundreds of million dollars to complete eradication of polio.very good move, citizens should be proud of their country
  • A
    Andrew
    Andrew

    The new CEO Emma Walmsley is going to eclipse Marissa Mayer as a CEO and make GSK into #1 pharma soon
    The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
    https://endpts.com/the-big-revamp-at-glaxosmithkline-rd-includes-a-new-collaboration-on-ai/

    The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
    A few weeks ago, when GlaxoSmithKline said it had recruited Pfizer vet Tony Wood to run the platform tech and science group in the pharma R&D operation, the company noted that he was taking the place of John Baldoni, a senior research exec who was la
    endpts.com
  • A
    Anonymous
    Anonymous
    Fortunately, I did not buy GSK yesterday to get today's dividend of $0.49. I would lose additional $0.3. Not worth it. Short term momentum is negative. I expect the stock will continue down with no upward news.
  • A
    Anonymous
    Anonymous
    Some products made tiny sales. Reshape R&D necessary. But it takes long time. Short term, negative. Heading to $38.
  • J
    John
    John
    ...going to realize some return for its shareholders??? WHEN?
  • J
    John
    John
    Wonder what's today's excuse for the big pre-market drop in GSK's share price?? Perhaps paying huge bonuses to their less-than-able executives and senior management?? When is this poor excuse for a pharmaceutical company
  • d
    desert rat
    desert rat
    GSK has all the right parts and pieces to put it on top, then again - so did Kodak. I'm a long time holder of this disappointing stock and I sure hope changes in management makes some measurable difference to its performance.
  • r
    roger
    roger
    CEO is moving the company away from development of cures or rare exotic diseases for which there is little commercial potential to development of drugs to treat diseases that affect a large population that have far greater market potential. It will take a few years to see the benefits of this change, but is the right decision. Buy GSK as an investment, not a day trade for a quick profit.
  • n
    nito
    nito

    Needle-Free Vaccines~~ To Disrupt the Vaccine Industry

    http://www.businesswire.com/news/home/20170810005176/en/

    video/// https://vimeo.com/227783144

    No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
    The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.
    www.businesswire.com
  • J
    JoAnn
    JoAnn
    New leadership from someone who really knows the company, expanding pipeline, low risk and sweet dividend.
  • J
    Joe
    Joe
    45 to 40 in the blink of a eye.
  • S
    Scott
    Scott

    FDA approval
    https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-a-new-self-injectable-formulation-of-benlysta-belimumab-for-systemic-lupus-erythematosus/

    GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus | GSK
    GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody positive SLE who are receiving standard therapy. Syst
    www.gsk.com
  • B
    B
    B
    Once again GSK has proved it consists of the largest number of incompetent scientists in the industry. It is really nothing more than a vaccines company and full of scientists who could not get jobs at better pharma companies. GSK gets the "leftovers"!
  • B
    Boyd
    Boyd
    MRNS receives orphan drug status stock is up 5 days in a row. Only 21 million shares in float.
  • L
    Leon
    Leon
    can't believe GSK dropped from 45, who can tell me why?
  • C
    Charlesh
    Charlesh
    Cup and handle on today's minute chart. I believe the bottom is in. Hold on tight.
  • F
    Fred B
    Fred B
    Do you have to pay foreign tax on the dividends?